Eden Biodesign Expands US operations
Eden Biodesign, Ltd. (Liverpool, UK), has confirmed its expansion plans for Eden Biodesign, Inc., the Group’s US subsidiary, with the announcement of a facility in the highly coveted biotech hub, Research Triangle Park, NC.
Eden Biodesign, Ltd. (Liverpool, UK), has confirmed its expansion plans for Eden Biodesign, Inc., the Group’s US subsidiary, with the announcement of a facility in the highly coveted biotech hub, Research Triangle Park, NC.
Building on the recent growth of its UK cGMP facility, Eden Biodesign, Inc., will offer a range of cell line/strain development and early process-development services. Eden Biodesign provides services in support of all major biopharmaceutical production technologies (mammalian, microbial, and viral) and offers a toolbox of expression technologies, some through collaboration with partner companies.
Eden Biodesign is further cementing its commitment to the North American market with the recent appointment of Michael Faughnan as business development director, who will be supporting the company’s expansion into the North American market from Southern California. The company is actively developing technology and marketing collaborations with industry leaders throughout North America.
Eden release (PDF)
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
